Grufity logoGrufity logo

Medtronic PLC Stock Research

MDT

80.55USD+1.37(+1.73%)Market Closed

Market Summary

USD80.55+1.37
Market Closed
1.73%

MDT Stock Price

MDT RSI Chart

MDT Valuation

Market Cap

105.3B

Price/Earnings (Trailing)

25.91

Price/Sales (Trailing)

3.42

EV/EBITDA

14.12

Price/Free Cashflow

25.29

MDT Price/Sales (Trailing)

MDT Profitability

EBT Margin

17.60%

Return on Equity

7.88%

Return on Assets

4.32%

Free Cashflow Yield

3.95%

MDT Fundamentals

MDT Revenue

Revenue (TTM)

30.8B

Revenue Y/Y

-0.46%

Revenue Q/Q

1.87%

MDT Earnings

Earnings (TTM)

4.1B

Earnings Y/Y

-17.43%

Earnings Q/Q

186.18%

Price Action

52 Week Range

75.10113.44
(Low)(High)

Last 7 days

-0.1%

Last 30 days

-4.4%

Last 90 days

1.9%

Trailing 12 Months

-28.5%

MDT Financial Health

Current Ratio

1.76

Debt/Equity

0.43

Debt/Cashflow

0.25

MDT Investor Care

Dividend Yield

3.44%

Dividend/Share (TTM)

2.72

Buy Backs (1Y)

0.91%

Diluted EPS (TTM)

3.04

Peers (Alternatives to Medtronic)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
105.3B
30.8B
-4.37% -28.48%
25.91
3.42
-3.19% -17.38%
88.0B
6.2B
9.55% -17.45%
66.52
14.14
8.97% -22.43%
49.6B
5.4B
1.40% -30.34%
32.6
9.22
2.86% 1.25%
24.1B
3.7B
0.76% -29.47%
66.64
6.45
-5.51% -53.17%
19.9B
4.5B
1.08% 5.00%
20.11
4.46
-18.71% -42.28%
MID-CAP
10.6B
847.1M
6.58% 27.77%
-5.3K
12.46
13.32% -137.89%
6.6B
2.6B
3.10% -18.44%
27.03
2.56
2.40% -18.20%
3.1B
1.0B
7.16% -31.03%
-38.98
3
3.45% -228.84%
2.4B
93.5M
-7.87% 185.38%
-65.44
25.37
208.83% 18.06%
2.3B
1.0B
-9.74% -47.60%
-26.53
2.24
-1.31% 36.50%
SMALL-CAP
1.7B
161.7M
-5.36% -0.91%
-22.01
10.24
27.64% -82.82%
1.3B
820.0M
2.39% -14.54%
26.48
1.63
10.13% 701.59%
887.4M
154.8M
-10.66% -9.26%
-8.53
5.73
60.29% -2309.58%
278.7M
377.2M
-22.46% -62.75%
-3.33
0.74
5.37% -1222.79%
46.6M
470.7M
-35.97% -85.77%
-0.54
0.1
-26.17% 15.66%

Financials for Medtronic

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue-0.1%30,77230,80831,07031,68631,785
  S&GA Expenses0.5%10,36810,31410,31210,29210,318
EBITDA-2.0%8,7148,8919,0128,777-
EBITDA Margin-1.9%0.28*0.29*0.29*0.28*-
Earnings Before Taxes-3.8%5,4165,6305,7285,5175,481
EBT Margin-3.7%0.18*0.18*0.18*0.17*-
Interest Expenses5.3%592562580553552
Net Income-6.0%4,0654,3235,2075,0394,920
Net Income Margin-5.9%0.13*0.14*0.17*0.16*-
Free Cahsflow-13.6%4,1664,8225,7215,978-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets1.0%94,13493,24189,91490,98191,804
  Current Assets-0.1%25,36425,39822,13523,05923,303
    Cash Equivalents-6.4%4,5214,8282,1403,7143,479
  Inventory6.3%5,3755,0554,8094,6164,514
  Net PPE2.6%5,4375,2985,2815,4135,251
  Goodwill2.8%41,56540,41740,32440,50241,346
Liabilities3.2%42,51641,18437,07138,26039,091
  Current Liabilities-0.3%14,42214,46514,04912,3948,927
  Long Term Debt7.0%22,21020,75317,48120,37224,290
Shareholder's Equity-0.5%51,61851,88052,84352,55152,542
  Retained Earnings1.1%30,11729,79930,27630,25029,607
  Additional Paid-In Capital0.3%24,51324,44224,33524,56625,814
Accumulated Depreciation3.5%8,4898,1998,0437,9527,823
Shares Outstanding0.0%1,3301,3301,3291,3311,343
Minority Interest0%177177170171171
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-10.4%5,6366,2907,1377,3467,034
  Share Based Compensation0.9%352349352359356
Cashflow From Investing5.2%-2,747-2,897-2,460-1,659-11.00
Cashflow From Financing-90.1%-2,019-1,062-5,231-5,336-8,516
  Dividend Payments1.6%3,5543,4973,4403,3833,321
  Buy Backs-14.1%1,8872,1962,4692,5441,616

Risks for MDT

What is the probability of a big loss on MDT?

46.5%


Probability that Medtronic stock will be more than 20% underwater in next one year

32.7%


Probability that Medtronic stock will be more than 30% underwater in next one year.

0%


Probability that Medtronic stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does MDT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Medtronic was unfortunately bought at previous high price.

Drawdowns

Returns for MDT

Cumulative Returns on MDT

7.6%


10-Year Cumulative Returns

2.8%


7-Year Cumulative Returns

1.7%


5-Year Cumulative Returns

-3.2%


3-Year Cumulative Returns

What are the long-term rolling returns for MDT?

FIve years rolling returns for Medtronic.

Annualized Returns

Which funds bought or sold MDT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-17
American Portfolios Advisors
added
32.5
512,240
3,178,580
0.14%
2023-03-15
B. Riley Wealth Advisors, Inc.
reduced
-4.21
-192,074
2,503,930
0.07%
2023-03-13
Claro Advisors LLC
added
36.89
101,369
650,369
0.21%
2023-03-10
MATHER GROUP, LLC.
reduced
-11.21
-142,091
835,909
0.02%
2023-03-10
BAILLIE GIFFORD & CO
added
1.07
-948,671
33,858,300
0.04%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-5.3
-11,099,700
114,288,000
0.12%
2023-03-08
Capital Asset Advisory Services LLC
reduced
-18.5
-89,147
403,853
0.03%
2023-03-07
Great Lakes Retirement, Inc.
new
-
751,083
751,083
0.19%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-63.1
-95,801,000
52,760,000
0.26%
2023-03-06
NORTH STAR ASSET MANAGEMENT INC
reduced
-2.5
-24,416
379,584
0.02%

1–10 of 48

Latest Funds Activity

Are funds buying MDT calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own MDT
No. of Funds

Medtronic News

MarketBeat

CAPROCK Group Inc. Sells 6702 Shares of Medtronic plc (NYSE ....

MarketBeat,
27 hours ago

InvestorsObserver

The Business Journals

Marketscreener.com

Schedule 13G FIlings of Medtronic

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 15, 2023
blackrock inc.
9.2%
122,349,678
SC 13G/A
Feb 09, 2023
vanguard group inc
9.41%
125,126,702
SC 13G/A
Feb 01, 2022
blackrock inc.
8.0%
107,903,361
SC 13G/A
Feb 10, 2021
vanguard group inc
8.27%
111,286,018
SC 13G/A
Feb 03, 2021
wellington management group llp
2.87%
38,648,749
SC 13G/A
Jan 29, 2021
blackrock inc.
7.96%
107,107,760
SC 13G/A
Feb 12, 2020
vanguard group inc
8.55%
114,617,479
SC 13G/A
Feb 05, 2020
blackrock inc.
8.2%
109,561,921
SC 13G/A
Jan 27, 2020
wellington management group llp
5.13%
68,769,139
SC 13G/A

MDT Fair Value

Medtronic fair value in different scenarios

The table shows the Fair Value estimates for Medtronic for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

35.91

-55.42%

41.64

-48.31%

52.06

-35.37%

70.57

-12.39%

85.32

5.92%
Current Inflation

33.90

-57.91%

38.84

-51.78%

47.68

-40.81%

63.17

-21.58%

75.31

-6.51%
Very High Inflation

31.40

-61.02%

35.42

-56.03%

42.43

-47.32%

54.54

-32.29%

63.82

-20.77%

Historical Medtronic Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Medtronic

View All Filings
Date Filed Form Type Document
Mar 30, 2023
8-K
Current Report
Mar 24, 2023
424B5
Prospectus Filed
Mar 24, 2023
FWP
Prospectus Filed
Mar 23, 2023
424B3
Prospectus Filed
Mar 15, 2023
25-NSE
25-NSE
Mar 10, 2023
25-NSE
25-NSE
Mar 09, 2023
8-K
Current Report
Mar 07, 2023
8-K
Current Report
Mar 03, 2023
S-3ASR
S-3ASR
Mar 01, 2023
10-Q
Quarterly Report

Latest Insider Trading transactions for MDT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-02-01
Kirk Jennifer M
sold (taxes)
-57,637
85.77
-672
chief accounting officer
2022-12-13
Salmon Sean
acquired
920,027
55.32
16,631
evp & president cardiovascular
2022-12-13
Salmon Sean
sold
-1,338,740
80.4964
-16,631
evp & president cardiovascular
2022-12-09
Fong Ivan K
sold (taxes)
-409,140
78.59
-5,206
evp general counsel & secr
2022-12-07
WHITE ROBERT JOHN
sold (taxes)
-27,505
79.04
-348
evp & pres. medical surgical
2022-12-07
Wall Brett A.
sold (taxes)
-26,636
79.04
-337
evp & pres neuroscience
2022-12-07
Salmon Sean
sold (taxes)
-23,712
79.04
-300
evp & president cardiovascular
2022-10-14
TEN HOEDT ROB
sold
-196,015
81.537
-2,404
evp and pres. global regions
2022-10-14
TEN HOEDT ROB
acquired
100,006
41.6
2,404
evp and pres. global regions
2022-08-01
Smith Gregory L
acquired
-
-
5,587
evp global ops & supply chain

1–10 of 50

Geoffrey S. Martha
65535
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.

MDT Income Statement

2023-01-27
Consolidated Statements of Income (Unaudited) - USD ($)
shares in Millions
3 Months Ended9 Months Ended
Jan. 27, 2023
Jan. 28, 2022
Jan. 27, 2023
Jan. 28, 2022
Income Statement [Abstract]    
Net sales$ 7,727,000,000$ 7,763,000,000$ 22,682,000,000$ 23,597,000,000
Costs and expenses:    
Cost of products sold, excluding amortization of intangible assets2,689,000,0002,459,000,0007,740,000,0007,554,000,000
Research and development expense688,000,000668,000,0002,055,000,0002,094,000,000
Selling, general, and administrative expense2,615,000,0002,561,000,0007,799,000,0007,723,000,000
Amortization of intangible assets431,000,000432,000,0001,275,000,0001,298,000,000
Restructuring charges, net38,000,00012,000,00081,000,00032,000,000
Certain litigation charges, net035,000,000095,000,000
Other operating (income) expense, net(125,000,000)(63,000,000)(187,000,000)719,000,000
Operating profit1,392,000,0001,659,000,0003,920,000,0004,081,000,000
Other non-operating income, net(149,000,000)(67,000,000)(342,000,000)(244,000,000)
Interest expense, net167,000,000137,000,000449,000,000410,000,000
Income before income taxes1,375,000,0001,589,000,0003,813,000,0003,915,000,000
Income tax provision146,000,000106,000,0001,218,000,000346,000,000
Net income1,229,000,0001,483,000,0002,595,000,0003,570,000,000
Net income attributable to noncontrolling interests(6,000,000)(4,000,000)(17,000,000)(16,000,000)
Net income attributable to Medtronic$ 1,222,000,000$ 1,480,000,000$ 2,579,000,000$ 3,554,000,000
Basic earnings per share (usd per share)$ 0.92$ 1.10$ 1.94$ 2.64
Diluted earnings per share (usd per share)$ 0.92$ 1.10$ 1.94$ 2.63
Basic weighted average shares outstanding (shares)1,330.21,343.71,329.61,344.4
Diluted weighted average shares outstanding (shares)1,332.01,350.31,332.81,353.9

MDT Balance Sheet

2023-01-27
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Jan. 27, 2023
Apr. 29, 2022
Current assets:  
Cash and cash equivalents$ 4,521$ 3,714
Investments6,6166,859
Accounts receivable, less allowances and credit losses of $207 and $230, respectively5,8875,551
Inventories, net5,3754,616
Other current assets2,9652,318
Total current assets25,36423,059
Property, plant, and equipment13,92613,365
Accumulated depreciation(8,489)(7,952)
Property, plant, and equipment, net5,4375,413
Goodwill41,56540,502
Other intangible assets, net15,26515,595
Tax assets3,3613,403
Other assets3,1423,008
Total assets94,13490,981
Current liabilities:  
Current debt obligations5,9183,742
Accounts payable2,2092,276
Accrued compensation2,0072,121
Accrued income taxes657704
Other accrued expenses3,6303,551
Total current liabilities14,42212,394
Long-term debt22,21020,372
Accrued compensation and retirement benefits1,1031,113
Accrued income taxes2,3052,087
Deferred tax liabilities747884
Other liabilities1,7301,410
Total liabilities42,51638,260
Commitments and contingencies (Note 16)
Shareholders’ equity:  
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,330,376,287 and 1,330,743,395 shares issued and outstanding, respectively00
Additional paid-in capital24,51324,566
Retained earnings30,11730,250
Accumulated other comprehensive loss(3,189)(2,265)
Total shareholders’ equity51,44152,551
Noncontrolling interests177171
Total equity51,61852,722
Total liabilities and equity$ 94,134$ 90,981